Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

SB Dusetzina, AN Winn, GA Abel… - Journal of Clinical …, 2014 - ascopubs.org
Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …
被引用次数：548 相关文章
[PDF] archive.org

[PDF][PDF] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

SB Dusetzina, AN Winn, GA Abel, HA Huskamp… - 2013 - scholar.archive.org
Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

SB Dusetzina, AN Winn, GA Abel… - Journal of clinical …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.

SB Dusetzina, AN Winn, GA Abel… - Journal of Clinical …, 2013 - europepmc.org
Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

[引用][C] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

SB DUSETZINA, AN WINN, GA ABEL… - Journal of clinical …, 2014 - pascal-francis.inist.fr
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic
Myeloid Leukemia CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
[PDF] populationmedicine.org

[PDF][PDF] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

SB Dusetzina, AN Winn, GA Abel, HA Huskamp… - 2013 - populationmedicine.org
Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

SB Dusetzina, AN Winn, GA Abel… - Journal of Clinical …, 2014 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> The introduction of imatinib, a tyrosine
kinase inhibitor (TKI), has greatly increased survival for patients with chronic myeloid …

[引用][C] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

SB Dusetzina, AN Winn, GA Abel, HA Huskamp… - J Clin Oncol, 2013